<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CARBOPLATIN</span><br/>(car-bo-pla'tin)<br/><span class="topboxtradename">Paraplatin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 150 mg, 450 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Carboplatin is a platinum compound that is a chemotherapeutic agent. It produces interstrand DNA cross-linkages, thus interfering
         with DNA, RNA, and protein synthesis. Carboplatin is cell-cycle nonspecific, i.e., effective throughout the entire cell life
         cycle.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Full or partial activity against a variety of cancers resulting in reduction or stabilization of tumor size and useful in
         patients with impaired renal function, patients unable to accommodate high-volume hydration, or patients at high risk for
         neurotoxicity and/or ototoxicity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Monotherapy or combination therapy for ovarian cancer.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Combination therapy for breast, cervical, colon, endometrial, head and neck, and lung cancer; leukemia, lymphoma, and melanoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of severe reactions to carboplatin or other platinum compounds, severe bone marrow depression; significant bleeding;
         impaired renal function; pregnancy (category D), and lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Use with other nephrotoxic drugs.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ovarian Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 360 mg/m<sup>2</sup> once q4wk. May be repeated when neutrophil count is at least 2000 mm<sup>3</sup> and platelet count is at least 100,000 mm<sup>3</sup>. If neutrophil and platelet counts are lower, dose of carboplatin should be reduced by 5075% of initial dose. Alternatively,
               400 mg/m<sup>2</sup> as a 24-h infusion for 2 consecutive d can be used<br/><br/><span class="indicationtitle">Head and Neck and Small Cell Lung Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 300400 mg/m<sup>2</sup> q4wk<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> Up to 560 mg/m<sup>2</sup> once q4wk or up to 175 mg/m<sup>2</sup> q2wk. Other dosage regimens have been used for specific dosing protocols<br/><br/><p><span class="rdpostnotetitle">Important Note</span><br/><span class="rdpostnotetext">Aluminum reacts with carboplatin to form an inactive precipitate; therefore, intravenous infusion sets and needles containing
                     aluminum should not be used.</span></p>
</td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Do not use needles or IV sets containing aluminum. Immediately before use, reconstitute with either sterile water for injection
                  or D5W or NS as follows: 50-mg vial plus 5 mL diluent; 150-mg vial plus 15 mL diluent; 450-mg vial plus 45 mL diluent. All
                  dilutions yield 10 mg/mL. May be further diluted to 0.5 mg/mL with D5W or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give IV solution over 15 min or longer, depending on total amount of solution and patient tolerance. Lengthening duration
                  of administration may decrease nausea and vomiting.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Sodium bicarbonate,</b>
<b>fluorouracil,</b>
<b>mesna. </b>
<span class="incompattype">Y-site:</span>
<b> Amphotericin B cholesteryl complex.</b>
</p>
<ul>
<li>Premedication with a parenteral antiemetic ½ h before and on a scheduled basis thereafter is normally used.</li>
<li>Do not repeat doses until the neutrophil count is at least 2000/mm<sup>3</sup> and platelet count at least 100,000/mm<sup>3</sup>.
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Protect from light. Reconstituted solutions are stable for 8 h at room temperature; discard solutions 8 h after dilution.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Hypersensitivity reactions. <span class="typehead">GI:</span>
<span class="speceff-common">Mild to moderate nausea and vomiting,</span> anorexia, hypogeusia, dysgeusia, mucositis, diarrhea, constipation, elevated liver enzymes. <span class="typehead">Hematologic:</span>
<span class="speceff-both">Thrombocytopenia, leukopenia, neutropenia, anemia</span>. <span class="typehead">Metabolic:</span>
<span class="speceff-common">Mild hyponatremia, hypomagnesemia, hypocalcemia, and hypokalemia.</span>
<span class="typehead">CNS:</span> Peripheral neuropathy. <span class="typehead">Skin:</span> Rash, alopecia. <span class="typehead">Special Senses:</span> Tinnitus. <span class="typehead">Urogenital:</span> Nephrotoxicity. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Decreased <span class="alt">calcium levels;</span> mild increases in <span class="alt">liver function tests;</span> decreased levels of <span class="alt">magnesium,</span>
<span class="alt">potassium,</span> and <span class="alt">sodium.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">aminoglycosides</span> may increase the risk of ototoxicity and nephrotoxicity. May decrease <b>phenytoin</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 8 wk (2 cycles). <span class="typehead">Duration:</span> 216 mo. <span class="typehead">Distribution:</span> Highest concentration is seen in the liver, lung, kidney, skin, and tumors. Not bound to plasma proteins. <span class="typehead">Metabolism:</span> Hydrolyzed in the serum. <span class="typehead"> Elimination:</span> Primarily eliminated by the kidneys; 6080% excreted in urine within 24 h. <span class="typehead">Half-Life:</span> 3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely during first 15 min of infusion, since allergic reactions have occurred within minutes of carboplatin administration.</li>
<li>Lab tests: Baseline and periodic CBC with differential, platelet count, Hgb and Hct. Monitor periodically kidney function
            with creatinine clearance tests and serum electrolytes.
         </li>
<li>Monitor results of peripheral blood counts. Median nadir occurs at day 21. Leukopenia, neutropenia, and thrombocytopenia are
            dose related and may produce dose-limiting toxicity.
         </li>
<li>Monitor for peripheral neuropathy (e.g., paresthesias), ototoxicity, and visual disturbances.</li>
<li>Monitor serum electrolyte studies, because carboplatin has been associated with decreases in sodium, potassium, calcium, and
            magnesium. Special precautions may be warranted for patients on diuretic therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn about the range of potential adverse effects. Strategies for nausea prevention should receive special attention.</li>
<li>During therapy you are at risk for infection and hemorrhagic complications related to bone marrow suppression. Avoid unnecessary
            exposure to crowds or infected persons during the nadir period.
         </li>
<li>Report paresthesias (numbness, tingling), visual disturbances, or symptoms of ototoxicity (hearing loss and/or tinnitus).</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>